药明巨诺-B(02126.HK)：已向国家药监局递交瑞基奥仑赛在中国成人活动性系统性红斑狼疮患者中的I期研究数据

Core Viewpoint - WuXi AppTec's subsidiary, WuXi Biologics, has submitted Phase I study data for relma-cel in adult patients with active systemic lupus erythematosus (SLE) to the National Medical Products Administration (NMPA) in China, which has accepted the data and processed the meeting application [1] Group 1 - WuXi Biologics has initiated a Phase I clinical trial for relma-cel targeting SLE patients [1] - The submission to NMPA indicates progress in the regulatory process for relma-cel in China [1] - Acceptance of the data by NMPA is a significant step towards potential market entry [1]